Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06551337

Vitamin D Replacement in Bronchiectasis

Prospective Clinical Study on Vitamin D Replacement in Bronchiectasis - A Pilot Study

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
104 (estimated)
Sponsor
Queen Mary Hospital, Hong Kong · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study seeks to address the limitations in previous related studies on vitamin D replacement and bronchiectasis exacerbation occurrence through a self-controlled pilot study. The investigators aim to investigate whether vitamin D replacement in bronchiectasis patients with vitamin D deficiency can reduce hospitalized bronchiectasis exacerbation occurrence. Patients who participated in the prior study entitled "Prospective clinical study on serum 25-hydroxyvitamin D (25-OH D) level and risk of bronchiectasis exacerbation" (UW 22-317) will be invited for participation during regular clinic follow-up and management in Queen Mary Hospital. If participants are willing to join the further research, participants will be recruited in this self-controlled study. There are some differences from usual management to non-CF bronchiectasis subjects. The study subjects would be checked for their blood 25-hydroxyvitamin-D level during the study period. The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU (if needed). The investigators aim to correct their Vitamin D deficiency completely, aiming at blood 25-hydroxyvitamin-D level \>=50, i.e. treat to target. The dose depends on the level of Vitamin D after replacement. If blood 25-hydroxyvitamin-D level is 50 or above, then 1000 IU is suffice. If blood 25-hydroxyvitamin-D level is still below 50, the investigators will increase to 2000 IU.

Conditions

Interventions

TypeNameDescription
DRUGVitamin D3The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.

Timeline

Start date
2024-04-17
Primary completion
2026-12-31
Completion
2027-06-30
First posted
2024-08-13
Last updated
2024-08-13

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT06551337. Inclusion in this directory is not an endorsement.